Breaking News

Shots Fired at Canada War Memorial, Soldier Down
Tweet TWEET

Companies Announce Partnerships, Deployment of Services and Financial Results - Research Report on DaVita, BD, Allscripts,

Companies Announce Partnerships, Deployment of Services and Financial Results
     - Research Report on DaVita, BD, Allscripts, MedAssets, and Receptos

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 19, 2013

NEW YORK, November 19, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting DaVita
HealthCare Partners Inc. (NYSE: DVA), Becton, Dickinson and Company (NYSE:
BDX), Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), MedAssets, Inc.
(NASDAQ: MDAS), and Receptos, Inc. (NASDAQ: RCPT). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

DaVita HealthCare Partners Inc. Research Report 

On November 13, 2013, DaVita HealthCare Partners Inc. (DaVita HealthCare)
reported that its dialysis division, DaVita® has collaborated with a leading
provider of kidney care services, Shanghai Yangpu Antu Hospital (SYAH) to
improve the quality of life among dialysis patients while controlling or
minimizing medical expenses. DaVita HealthCare informed that with support of
the district government and approval from the health bureau, DaVita® and SYAH
are establishing a Renal Dialysis Technology Collaboration Base at the 400-bed
hospital. Under the terms of the agreement, the partnership will upgrade
clinic technology, expand the number of dialysis stations, and bring its
industry-leading quality of care and resulting clinical outcomes to the
hospital.  Dennis Kogod, DaVita's Chief Operating Officer, said, "The end
stage renal disease population in China is the ultimate beneficiary of this
collaboration. Not only does it promote health care quality improvement,
safety and therapeutic effectiveness, we believe it will minimize medical
expenses and lead to overall quality of life improvement for patients." The
Full Research Report on DaVita HealthCare Partners Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/5986_DVA

--

Becton, Dickinson and Company Research Report 

On November 13, 2013, Becton, Dickinson and Company (BDC) reported that it has
joined the National Patient Safety Foundation Corporate Council (NPSFCC),
which would enable the Company to work along with the latter and its
constituent groups to raise awareness of patient safety issues and create
solutions that address them. Bill Kozy, Executive Vice President, BDC,
commented, "Our drive to create a safer healthcare system is deeply rooted in
BD's commitment to improving access and outcomes of healthcare. We are honored
to stand alongside the National Patient Safety Foundation in discussing the
actions needed to improve patient safety, with a particular emphasis on
ensuring safe preparation and administration of medications. In this mission,
we recognize the need to improve clinical outcomes while simultaneously
lowering the cost of care and are committed to creating solutions that do
both." The Full Research Report on Becton, Dickinson and Company - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/0175_BDX

--

Allscripts Healthcare Solutions, Inc. Research Report

On November 8, 2013, Allscripts Healthcare Solutions, Inc. (Allscripts)
reported that it has entered into an agreement with the newly-established
hospitals, Montefiore New Rochelle and Montefiore Mount Vernon to expand the
relationship at those locations. According to the Company, the partnership
will upgrade both hospitals to Allscripts Sunrise™ 6.1 Integrated Electronic
Health Record as well as the Sunrise Clinical Analytics™, Sunrise Radiology™
and Sunrise Laboratory™. Paul M. Black, President and CEO of Allscripts,
commented, "Allscripts has been committed to these hospitals for many years
and we are pleased Montefiore decided to continue the agreement. Sunrise 6.1
is a fully integrated EHR solution, with a growing track record of successful
implementations, and is designed to effectively manage regulatory requirements
and evolving business needs. The powerful combination of our solutions will
help ensure the continued delivery of exceptional patient care." The Full
Research Report on Allscripts Healthcare Solutions, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/1787_MDRX

--

MedAssets, Inc. Research Report

On November 11, 2013, MedAssets, Inc. (MedAssets) reported that Jupiter
Medical Center, a non-profit regional medical center in Jupiter, Florida, has
recently selected the Company's consulting and technology-enabled services to
improve operational efficiency and reduce the total cost of care. Dale
Hocking, Vice President and CFO, Jupiter Medical Center, commented, "As
healthcare continues to evolve toward a value-based system, our relationship
with MedAssets will assist in expanding our traditional cost management
approach to a broader, more strategic vision that aligns the cost of care with
clinical outcomes." He added, "MedAssets has the experience, expertise and
technology to help us develop a holistic approach to performance improvement
that creates sustainable savings and delivers effective and efficient patient
care at optimal cost." The Full Research Report on MedAssets, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/0913_MDAS

--

Receptos, Inc. Research Report

On October 30, 2013, Receptos, Inc. (Receptos) reported its Q3 2013 financial
results. Net loss was $15.6 million, or $0.88 per share, versus a net loss of
$6.0 million, or $4.44 per share, in Q3 2012. Receptos' total revenues were
$1.1 million, versus $1.8 million in Q3 2012. Research and development (R&D)
expenses were $13.5 million, versus $6.8 million in Q3 2012. Faheem Hasnain,
CEO of Receptos, commented, "We continue to execute on our Phase 2 trials of
RPC1063 in relapsing multiple sclerosis (RMS) and ulcerative colitis (UC).
Having now completed enrollment in the RMS trial, our timeline for reporting
top-line data in mid-2014 is maintained. In addition, we look forward to the
interim review of the RMS trial later this quarter, which will gate our
decision to initiate Phase 3 in the coming weeks." The Full Research Report on
Receptos, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/aabc_RCPT

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.